The DOI matches its Crossref record; its reference list is not available.
GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease
Open accessPublished version of a preprint
Abstract
OBJECTIVE: We assessed the effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on ischemic stroke prevention in the Asian population with type 2 diabetes (T2D) without established cardiovascular disease. RESEARCH DESIGN AND METHODS: This retrospective cohort study examined data obtained from the Taiwan National Health Insurance Research Database for the period from 1998 to 2018. The follow-up ended upon the occurrence of hospitalization for ischemic stroke. The median follow-up period was 3 years. The effect of GLP-1RA exposure time on the development of hospitalization for ischemic stroke was assessed. RESULTS: The GLP-1RA and non–GLP-1RA user groups both included 6,534 patients. Approximately 53% of the patients were women, and the mean age was 49 ± 12 years. The overall risk of ischemic stroke hospitalization for GLP-1RA users was not significantly lower than that for GLP-1RA nonusers (adjusted hazard ratio [HR] 0.69 [95% CI 0.47–1.00]; P = 0.0506), but GLP-1RA users with a >251-day supply during the study period had a significantly lower risk of ischemic stroke hospitalization than GLP-1RA nonusers (adjusted HR 0.28 [95% CI 0.11–0.71]). Higher cumulative dose of GLP-1 RAs (>1,784 mg) was associated with significantly lower risk of ischemic stroke hospitalization. The subgroup analyses defined by various baseline features did not reveal significant differences in the observed effect of GLP-1RAs. CONCLUSIONS: Longer use and higher dose of GLP-1 RAs were associated with a decreased risk of hospitalization for ischemic stroke among Asian patients with T2D who did not have established atherosclerotic cardiovascular diseases, but who did have dyslipidemia or hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 23 · Cited by 35
Research works printed but not linked: 16
- Hata, 2013, Epidemiology of stroke and coronary artery disease in Asia, Circ J, 77, 1923, 10.1253/circj.CJ-13-0786 · DOI
- Hsieh, 2014, Stroke: morbidity, risk factors, and care in Taiwan, J Stroke, 16, 59, 10.5853/jos.2014.16.2.59 · DOI
- Shah, 2015, Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people, Lancet Diabetes Endocrinol, 3, 105, 10.1016/S2213-8587(14)70219-0 · DOI · Paper page
- Wilcox, 2007, Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04), Stroke, 38, 865, 10.1161/01.STR.0000257974.06317.49 · DOI · Paper page
- Dardano, 2020, Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: which patients for GLP-1RA or SGLT-2 inhibitor?, Diabetes Res Clin Pract, 162, 108112, 10.1016/j.diabres.2020.108112 · DOI
- Han, 2016, A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat, Neuroreport, 27, 23, 10.1097/WNR.0000000000000490 · DOI
- Briyal, 2014, Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia, Neuroscience, 281, 269, 10.1016/j.neuroscience.2014.09.064 · DOI
- Nikolic, 2021, Liraglutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a real-world Setting of patients with type 2 diabetes: a novel anti-atherogenic effect, Diabetes Ther, 12, 261, 10.1007/s13300-020-00962-3 · DOI · Paper page
- Rizzo, 2014, Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study, Cardiovasc Diabetol, 13, 49, 10.1186/1475-2840-13-49 · DOI
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Hernandez, 2018, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet, 392, 1519, 10.1016/S0140-6736(18)32261-X · DOI · Paper page
- Huang, 2021, Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk, Sci Rep, 11, 1430, 10.1038/s41598-020-80753-9 · DOI
- Best, 2011, Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database, Diabetes Care, 34, 90, 10.2337/dc10-1393 · DOI
- Baviera, 2021, Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: a real-world study in two Italian cohorts, Diabetes Obes Metab, 23, 1484, 10.1111/dom.14361 · DOI
- Palmer, 2016, Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis, JAMA, 316, 313, 10.1001/jama.2016.9400 · DOI
- Monami, 2014, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials, Diabetes Obes Metab, 16, 38, 10.1111/dom.12175 · DOI
Metadata
- Authors
- Yang, Y.-S., Chen, H.-H., Huang, C.-N., Hsu, C. Y., Hu, K.-C., & Kao, C.-H.
- Affiliations
- Chung Shan Medical University Hospital (TW)
- Asia University Hospital (TW)
- China Medical University (TW)
- Asia University (TW)
- Corresponding author
- Kao, Chia-Hung
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-03-11
- Volume
- 45
- Issue
- 5
- Pages
- 1184-1192
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4221025718
- Cited by
- 35
- References
- 23
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 10 · 2023: 6 · 2022: 6
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Clinical Trial Center, China Medical University Hospital (DMR-111-105)
- China Medical University Hospital ((DMR-111-105)
- China Medical University (DMR-111-105)
- Division of Materials Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, ischemic stroke prevention, type 2 diabetes, stroke hospitalization, Asian patients, dose-response relationship, treatment duration, dyslipidemia, hypertension, cardiovascular risk
- MeSH terms
- Ischemic Stroke, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Ischemia, Male, Middle Aged, Retrospective Studies, Atherosclerosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
